Verzenio vs Tagrisso
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
| US Verzenio | US Tagrisso | |
|---|---|---|
| Generic name | abemaciclib | osimertinib |
| Drug class | CDK4/6 Inhibitor | EGFR Tyrosine Kinase Inhibitor |
| Treats | HR+/HER2- breast cancer | EGFR-positive non-small cell lung cancer |
| Category | Oncology | Oncology |
| Manufacturer | Eli Lilly | AstraZeneca |
| Year approved | 2017 | 2015 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $85M | — |
| Common side effects | Diarrhea, Low blood counts, Fatigue, Blood clots | Diarrhea, Rash, Dry skin, Lung inflammation |
Frequently asked questions
Is Verzenio or Tagrisso better?
Neither is universally "better." Verzenio (abemaciclib) and Tagrisso (osimertinib) are both used for oncology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Verzenio and Tagrisso?
Verzenio is a CDK4/6 Inhibitor made by Eli Lilly, while Tagrisso is a EGFR Tyrosine Kinase Inhibitor made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Verzenio has the larger estimated TV advertising budget of the two.